MedTrace Logo

Clinical Study of PAL-222 Targeting Patients With Refractory Skin Ulcer

NCT07016438 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-06-11

No results posted yet for this study

Summary

The goal of this clinical trial is to assess safety and efficacy in patients with with Refractory skin ulcer no response to existing therapy.

The main measures it aims to answer are:

* Investigation of adverse events
* Changes in clinical testing data
* Changes in vital signs Participants will have one PAL-222 transplanted to the ulcer site. Researchers will compare before and after the transplantation to see if any safety issues are recognized.

Conditions

  • Refractory Skin Ulcer

Interventions

PROCEDURE

Transplant surgery

One piece of PAL-222 is implanted into the ulcer area through the surgical procedure.

Sponsors & Collaborators

  • PharmaBio Corporation

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2025-12-01
Completion
2025-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07016438 on ClinicalTrials.gov